News

ParkourSC, a leader in AI-driven supply chain dynamic decision intelligence solutions, today announced its LEAP Partner ...
The market expects Organon (OGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is ...
Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...
BofA lowered the firm’s price target on Organon (OGN) to $11 from $15 and keeps an Underperform rating on the shares. The firm, in its preview ...
Bank of America Securities analyst Jason Gerberry maintained a Sell rating on Organon (OGN – Research Report) today and set a price target of ...